Identification
- Summary
Iron Dextran is an iron supplement used to treat iron deficiency in patients who cannot take oral iron.
- Brand Names
- Infed, Irospan 24/6 Kit
- Generic Name
- Iron Dextran
- DrugBank Accession Number
- DB00893
- Background
Iron dextran is a dark brown, slightly viscous liquid complex of ferric hydroxide and dextran for intravenous or intramuscular use. Iron Dextran is used for the treatment of patients with documented iron deficiency in which oral administration is unsatisfactory or impossible.
- Type
- Small Molecule
- Groups
- Approved, Vet approved
- Synonyms
- Dextran iron
- Iron Dextran
- Iron dextran complex
Pharmacology
- Indication
For treatment of patients with documented iron deficiency in whom oral administration is unsatisfactory or impossible. Also used to replenish body iron stores in Non-Dialysis Dependent-Chronic Kidney Disease (NDD-CKD) patients receiving or not receiving erythropoietin and in Hemodialysis Dependent (HDD-CKD) and Peritoneal Dialysis Dependent (PDD-CKD) - Chronic Kidney Disease patients receiving an erythropoietin.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Iron deficiency •••••••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Iron dextran is a dark brown, slightly viscous sterile liquid complex of ferric hydroxide and dextran for intravenous or intramuscular use. It is for treatment of patients with documented iron deficiency in whom oral administration is unsatisfactory or impossible. Iron is essential to the formation of hemoglobin and to the function and formation of other heme and nonheme compounds. Untreated depletion of iron stores leads to iron-deficient erythropoiesis and, in turn, to iron deficiency anemia.
- Mechanism of action
After iron dextran is injected, the circulating iron dextran is removed from the plasma by cells of the reticuloendothelial system, which split the complex into its components of iron and dextran. The iron is immediately bound to the available protein moieties to form hemosiderin or ferritin, the physiological forms of iron, or to a lesser extent to transferrin. This iron which is subject to physiological control replenishes hemoglobin and depleted iron stores.
Target Actions Organism AHemoglobin subunit beta activatorHumans AHemoglobin subunit alpha activatorHumans AFerritin heavy chain otherHumans AFerritin light chain otherHumans - Absorption
The major portion of intramuscular injections of iron dextran is absorbed within 72 hours; most of the remaining iron is absorbed over the ensuing 3 to 4 weeks.
- Volume of distribution
Not Available
- Protein binding
100% (after release from dextran)
- Metabolism
Dextran, a polyglucose, is either metabolized or excreted.
- Route of elimination
Dextran, a polyglucose, is either metabolized or excreted.
- Half-life
5 hours (some indications that it can be as long as 10 hours)
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
LD50 = 500 mg/kg (mouse, IV). Dosages of iron dextran in excess of the requirements for restoration of hemoglobin and replenishment of iron stores may lead to hemosiderosis. Cases of severe, sometimes fatal, allergic reactions (loss of consciousness, collapse, difficulty breathing, hives, swelling, or convulsions) and severe low blood pressure (hypotension) have been reported with the use of iron dextran.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAlmasilate Almasilate can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy. Aluminium phosphate Aluminium phosphate can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy. Aluminum hydroxide Aluminum hydroxide can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy. Benazepril The risk or severity of adverse effects can be increased when Benazepril is combined with Iron Dextran. Calcium carbonate Calcium carbonate can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy. - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Active Moieties
Name Kind UNII CAS InChI Key Iron unknown E1UOL152H7 7439-89-6 XEEYBQQBJWHFJM-UHFFFAOYSA-N Ferric cation ionic 91O4LML611 20074-52-6 VTLYFUHAOXGGBS-UHFFFAOYSA-N - Product Images
- International/Other Brands
- CosmoFer (B. Braun) / Feosol (GlaxoSmithKline) / Imferon (Sanofi-Aventis) / Proferdex (New River Pharmaceuticals Inc.)
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Dexferrum Injection, solution 50 mg/1mL Intravenous AMERICAN REGENT, INC. 1998-10-01 2013-04-22 US 
Dexferrum Injection, solution 50 mg/1mL Intravenous AMERICAN REGENT, INC. 1996-03-01 2013-04-08 US Dexiron Solution 50 mg / mL Intramuscular; Intravenous American Regent, Inc 1996-09-06 2022-05-12 Canada 
Infed Injection 50 mg/1mL Intramuscular; Intravenous General Injectables & Vaccines, Inc. 2019-01-21 2025-01-31 US Infed Injection 50 mg/1mL Intramuscular; Intravenous Henry Schein, Inc. 2022-01-11 Not applicable US - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image BiferaRx Iron Dextran (22 mg/1) + Cyanocobalamin (25 ug/1) + Folic acid (1 mg/1) + Heme iron polypeptide (6 mg/1) Tablet Oral Alaven Pharmaceutical LLC 2010-05-01 2019-09-30 US 
BiferaRx Iron Dextran (22 mg/1) + Cyanocobalamin (25 ug/1) + Folic acid (1 mg/1) + Heme iron polypeptide (6 mg/1) Tablet Oral MEDA Pharmaceuticals 2012-10-31 2018-09-30 US Iron Polysaccharides Folic Acid DHA Iron Dextran (29 mg/1) + Ascorbic acid (30 mg/1) + Beta carotene (1100 [iU]/1) + Cholecalciferol (1000 [iU]/1) + Cupric oxide (2 mg/1) + Cyanocobalamin (12 ug/1) + DL-alpha tocopheryl acetate (20 mg/1) + Doconexent (200 mg/1) + Folic acid (1 mg/1) + Magnesium oxide (20 mg/1) + Nicotinamide (15 mg/1) + Potassium Iodide (150 ug/1) + Pyridoxine hydrochloride (2.5 mg/1) + Riboflavin (1.8 mg/1) + Thiamine mononitrate (1.6 mg/1) + Zinc oxide (25 mg/1) Tablet, film coated Oral Virtus Pharmaceuticals 2013-12-20 2013-12-30 US Irospan 24/6 Iron Dextran (65 mg/1) + Biotin (300 ug/1) + Biotin (300 ug/1) + Calcium carbonate (100 mg/1) + Cyanocobalamin (10 ug/1) + Cyanocobalamin (10 ug/1) + Ferrous bisglycinate (65 mg/1) + Folic acid (1 mg/1) + Folic acid (1 mg/1) + Calcium formate (155 mg/1) + Niacin (25 mg/1) + Niacin (25 mg/1) + Calcium pantothenate (300 ug/1) + Calcium pantothenate (7 mg/1) + Pyridoxine hydrochloride (30 mg/1) + Pyridoxine hydrochloride (30 mg/1) + Riboflavin sodium (5 mg/1) + Riboflavin (5 mg/1) + Sodium ascorbate (100 mg/1) + Sodium ascorbate (100 mg/1) + Succinic acid (150 mg/1) + Thiamine hydrochloride (5 mg/1) + Thiamine hydrochloride (5 mg/1) Kit; Tablet; Tablet, film coated Oral WOMENS CHOICE PHARMACEUTICALS LLC 2011-04-15 Not applicable US Niferex Iron Dextran (100 mg/1) + Ascorbic acid (60 mg/1) + Cyanocobalamin (25 ug/1) + Ferrous asparto glycinate (50 mg/1) + Folic acid (250 ug/1) + Gastric intrinsic factor (100 mg/1) + Levomefolic acid (750 ug/1) + Succinic acid (50 mg/1) + Zinc (15 mg/1) Tablet Oral Avion Pharmaceuticals, Llc 2017-01-10 Not applicable US
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- 95HR524N2M
- CAS number
- 9004-66-4
- InChI Key
- Not Available
- InChI
- Not Available
- IUPAC Name
- Not Available
- SMILES
- Not Available
References
- Synthesis Reference
William T. Monte, Laurie Scaggs, "Process for making crystalline iron dextran." U.S. Patent US5756715, issued 1905.
US5756715- General References
- Iron dextran FDA LABEL [Link]
- External Links
- KEGG Drug
- D02141
- PubChem Substance
- 46506136
- 5992
- ChEMBL
- CHEMBL1201544
- Therapeutic Targets Database
- DAP001312
- PharmGKB
- PA164764618
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Iron_supplement
- MSDS
- Download (45.1 KB)
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 4 Completed Other Abnormal Uterine Bleeding / Heavy Menstrual Bleeding / Iron Deficiency Anemia (IDA) 1 4 Completed Treatment Delivery Complications / Iron Deficiency Anemia (IDA) 1 4 Completed Treatment Iron Deficiency Anemia of Pregnancy / Iron Malabsorption 1 4 Completed Treatment Treatment of Iron Deficiency Anemia in Pregnancy 1 4 Not Yet Recruiting Treatment Chronic Kidney Disease (CKD) / CKD - Chronic Kidney Disease 1
Pharmacoeconomics
- Manufacturers
- Luitpold pharmaceuticals inc
- Watson laboratories inc
- Sanofi aventis us llc
- New river pharmaceuticals inc
- Packagers
- Alaven Pharmaceutical
- American Regent
- General Injectables and Vaccines Inc.
- Gensavis LLC
- Luitpold Pharmaceuticals Inc.
- Patheon Inc.
- Physicians Total Care Inc.
- Primedics Laboratories
- Schein Pharmaceutical Inc.
- Watson Pharmaceuticals
- Dosage Forms
Form Route Strength Solution Intramuscular 100.000 mg Tablet Oral Injection, solution Intravenous Injection, solution Intravenous 50 mg/1mL Solution Intramuscular; Intravenous 50 mg / mL Injection Intravenous Solution Intravenous Injection Intramuscular Solution Parenteral 625.000 mg Injection Intramuscular; Intravenous 50 mg/ml Injection Intramuscular; Intravenous 50 mg/1mL Injection, solution Intramuscular; Intravenous 50 mg/1mL Liquid Intramuscular; Intravenous 50 mg / mL Solution Oral 100 MG/5ML Solution / drops Oral 50 MG/ML Capsule Oral Tablet, film coated Oral Kit; tablet; tablet, film coated Oral Solution Oral Capsule, gelatin coated Oral - Prices
Unit description Cost Unit Iron dextran comp 100 mg/2 ml 38.08USD ml Dexferrum 100 mg/2 ml vial 21.6USD ml Dexferrum 50 mg/ml vial 21.6USD ml Dexiron 50 mg/ml 15.66USD ml Infufer 50 mg/ml 15.53USD ml Infed 100 mg/2 ml vial 14.44USD ml DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US5624668 No 1997-04-29 2015-09-29 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source water solubility Soluble Not Available - Predicted Properties
- Not Available
- Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Activator
- General Function
- Oxygen transporter activity
- Specific Function
- Involved in oxygen transport from the lung to the various peripheral tissues.LVV-hemorphin-7 potentiates the activity of bradykinin, causing a decrease in blood pressure.Spinorphin: functions as an...
- Gene Name
- HBB
- Uniprot ID
- P68871
- Uniprot Name
- Hemoglobin subunit beta
- Molecular Weight
- 15998.34 Da
References
- Zaric J, Lazic D, Markovic S, Glisin V, Ivanovic Z, Milenkovic P, Popovic Z: Alpha- and beta-globins of the anemic Belgrade laboratory rat. II. The effect of hemin and iron-dextran treatment. Hemoglobin. 1998 May;22(3):231-44. [Article]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Activator
- General Function
- Oxygen transporter activity
- Specific Function
- Involved in oxygen transport from the lung to the various peripheral tissues.
- Gene Name
- HBA1
- Uniprot ID
- P69905
- Uniprot Name
- Hemoglobin subunit alpha
- Molecular Weight
- 15257.405 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Other
- General Function
- Iron ion binding
- Specific Function
- Stores iron in a soluble, non-toxic, readily available form. Important for iron homeostasis. Has ferroxidase activity. Iron is taken up in the ferrous form and deposited as ferric hydroxides after ...
- Gene Name
- FTH1
- Uniprot ID
- P02794
- Uniprot Name
- Ferritin heavy chain
- Molecular Weight
- 21225.47 Da
References
- Iron dextran FDA LABEL [Link]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Other
- General Function
- Iron ion binding
- Specific Function
- Stores iron in a soluble, non-toxic, readily available form. Important for iron homeostasis. Iron is taken up in the ferrous form and deposited as ferric hydroxides after oxidation. Also plays a ro...
- Gene Name
- FTL
- Uniprot ID
- P02792
- Uniprot Name
- Ferritin light chain
- Molecular Weight
- 20019.49 Da
References
- Iron dextran FDA LABEL [Link]
Carriers
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Transferrin receptor binding
- Specific Function
- Transferrins are iron binding transport proteins which can bind two Fe(3+) ions in association with the binding of an anion, usually bicarbonate. It is responsible for the transport of iron from si...
- Gene Name
- TF
- Uniprot ID
- P02787
- Uniprot Name
- Serotransferrin
- Molecular Weight
- 77063.195 Da
References
- Macdougall IC: Strategies for iron supplementation: oral versus intravenous. Kidney Int Suppl. 1999 Mar;69:S61-6. [Article]
- Salahudeen AK, Oliver B, Bower JD, Roberts LJ 2nd: Increase in plasma esterified F2-isoprostanes following intravenous iron infusion in patients on hemodialysis. Kidney Int. 2001 Oct;60(4):1525-31. [Article]
- Pai AB, Boyd AV, McQuade CR, Harford A, Norenberg JP, Zager PG: Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis. Pharmacotherapy. 2007 Mar;27(3):343-50. [Article]
- Jacobs JC, Alexander NM: Colorimetry and constant-potential coulometry determinations of transferrin-bound iron, total iron-binding capacity, and total iron in serum containing iron-dextran, with use of sodium dithionite and alumina columns. Clin Chem. 1990 Oct;36(10):1803-7. [Article]
- Speyer BE, Doney VJ, Fielding J: Transfer of iron from Ferastral and other organic complexes to transferrin as measured by reticulocyte uptake. Scand J Haematol Suppl. 1977;32:215-21. [Article]
Drug created at June 13, 2005 13:24 / Updated at February 20, 2024 23:54